Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
/L) after induction was 27 and 24 days, respectively. Overall, the treatment was safe and most grade 3 and 4 adverse events were infectious complications. The combination produced a high rate of remissions, translating into favorable outcomes for older patients with newly diagnosed AML. Trial Registration: ClinicalTrials.gov idetifier: NCT03586609.
Authors
- Farhad Ravandi (ORCID: https://orcid.org/0000-0002-7621-377X)
- Maro N. Ohanian (ORCID: https://orcid.org/0000-0002-1689-4470)
- X Wang
- Tapan Mahendra Kadia (ORCID: https://orcid.org/0000-0002-9892-9832)
- Koji Sasaki (ORCID: https://orcid.org/0000-0002-9140-0610)
- Álex Bataller (ORCID: https://orcid.org/0000-0002-6085-2745)
- Elizabeth Shpall
- Ian Bouligny (ORCID: https://orcid.org/0000-0002-4274-4249)
- Musa E. Yilmaz (ORCID: https://orcid.org/0000-0002-4498-4895)
- Caitlin R. Rausch (ORCID: https://orcid.org/0000-0002-4166-5717)
- Gautam M. Borthakur (ORCID: https://orcid.org/0000-0001-7679-6453)
- Alexandre Bazinet (ORCID: https://orcid.org/0000-0001-5538-4943)
- Yesid Alvarado (ORCID: https://orcid.org/0000-0002-1652-7937)
- Lucia Masárová (ORCID: https://orcid.org/0000-0001-6624-4196)
- N Jain
- Uday Popat
- Nicholas J. Short
- Hagop M. Kantarjian
- Courtney DiNardo
- Naveen Pemmaraju
- Wei Qiao
- Guillermo Garcia‐Manero
- Naval Daver
- Fadi G. Haddad
- Guillermo Montalban‐Bravo
- Sanam Loghavi
- Kelly Chien
- Ghayas C. Issa
- Abhishek Maiti
- Elias Jabbour
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- American Journal of Hematology
- Published
- 2026-04-25
- DOI
- https://doi.org/10.1002/ajh.70328
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Texas MD Anderson Cancer Center